Related references
Note: Only part of the references are listed.Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis
Kai Jiang et al.
PROTEIN & CELL (2022)
Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics
Zhenghong Liu et al.
THERANOSTICS (2021)
Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors JACC State-of-the-Art Review
Thomas A. Zelniker et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
TLR9 and beclin 1 crosstalk regulates muscle AMPK activation in exercise
Yang Liu et al.
NATURE (2020)
Sodium-glucose cotransporter 2 inhibitors: extending the indication to non-diabetic kidney disease?
Claire C. J. Dekkers et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2020)
The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease
Ken Ohara et al.
DIABETOLOGY & METABOLIC SYNDROME (2020)
Effects of Dapagliflozin on Epicardial Fat Thickness in Patients with Type 2 Diabetes and Obesity
Gianluca Iacobellis et al.
OBESITY (2020)
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
Martin R. Cowie et al.
NATURE REVIEWS CARDIOLOGY (2020)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
TLR9 Binding to Beclin 1 and Mitochondrial SIRT3 by a Sodium-Glucose Co-Transporter 2 Inhibitor Protects the Heart from Doxorubicin Toxicity
Chao-Yung Wang et al.
BIOLOGY-BASEL (2020)
Sodium-glucose cotransporter 2 inhibitor versus metformin as first-line therapy in patients with type 2 diabetes mellitus: a multi-institution database study
Tien-Hsing Chen et al.
CARDIOVASCULAR DIABETOLOGY (2020)
Canagliflozin Prevents Diabetes-Induced Vascular Dysfunction in ApoE-Deficient Mice
Arief Rahadian et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2020)
Impact of advanced glycation end products (AGEs) signaling in coronary artery disease
Marinos Kosmopoulos et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2019)
Uric acid and the cardio-renal effects of SGLT2 inhibitors
Clifford J. Bailey
DIABETES OBESITY & METABOLISM (2019)
Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats
Rachel J. Perry et al.
NATURE COMMUNICATIONS (2019)
Diabetes Mellitus and Cardiovascular Disease Emerging Therapeutic Approaches
Ann Marie Schmidt
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2019)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Effect of Empagliflozin on Endothelial Function in Patients With Type 2 Diabetes and Cardiovascular Disease: Results from the Multicenter, Randomized, Placebo-Controlled, Double-Blind EMBLEM Trial
Atsushi Tanaka et al.
DIABETES CARE (2019)
Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition
Pouya Saeedi et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Epicardial adipose tissue and cardiovascular diseases
Anna Maria Ansaldo et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
The SGLT2 Inhibitor Tofogliflozin Reduces Weight in People with Type 2 Diabetes due to Fluid Loss Initially and to Lipolysis in Late
Akihiro Yoshida et al.
DIABETES (2018)
Influence of SGLT2 Inhibitor on Resting Heart Rate (RHR) and Factors Related to Its Changes
Yasuhiro Matsubayashi et al.
DIABETES (2018)
SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management
Michael J. B. van Baar et al.
DIABETES CARE (2018)
Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis
Milton Packer
DIABETES OBESITY & METABOLISM (2018)
The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure
Merlin C. Thomas et al.
DIABETOLOGIA (2018)
The SGLT2 Inhibitor Dapagliflozin Significantly Improves the Peripheral Microvascular Endothelial Function in Patients with Uncontrolled Type 2 Diabetes Mellitus
Seigo Sugiyama et al.
INTERNAL MEDICINE (2018)
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
Hiddo J. L. Heerspink et al.
KIDNEY INTERNATIONAL (2018)
Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease
F. Bonnet et al.
DIABETES & METABOLISM (2018)
Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: Is low-grade inflammation the neglected component?
Francesco Prattichizzo et al.
DIABETES OBESITY & METABOLISM (2018)
Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Aidin Rawshani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity
Ningning Wan et al.
FRONTIERS IN ENDOCRINOLOGY (2018)
Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials
Yumo Zhao et al.
DIABETES OBESITY & METABOLISM (2018)
Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis
Karen M. Hallow et al.
DIABETES OBESITY & METABOLISM (2018)
The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE -/- mice fed a western diet
Ji Hye Han et al.
DIABETOLOGIA (2017)
Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: A meta-analysis of placebo-controlled randomized trials
Marwan Saad et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes
Shin Kawasoe et al.
BMC PHARMACOLOGY & TOXICOLOGY (2017)
SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice
Liang Xu et al.
EBIOMEDICINE (2017)
Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study
Anna Solini et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus
Kristina Striepe et al.
CIRCULATION (2017)
Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms
Bart Staels
AMERICAN JOURNAL OF MEDICINE (2017)
Renal Handling of Ketones in Response to Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 2 Diabetes
Ele Ferrannini et al.
DIABETES CARE (2017)
Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes
Javad Habibi et al.
CARDIOVASCULAR DIABETOLOGY (2017)
CV Protection in the EMPA-REG OUTCOME Trial: A Thrifty Substrate Hypothesis
Ele Ferrannini et al.
DIABETES CARE (2016)
Tofogliflozin Improves Insulin Resistance in Skeletal Muscle and Accelerates Lipolysis in Adipose Tissue in Male Mice
Atsushi Obata et al.
ENDOCRINOLOGY (2016)
Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
Heidi Storgaard et al.
PLOS ONE (2016)
Uric Acid as a Biomarker and a Therapeutic Target in Diabetes
Yuliya Lytvyn et al.
CANADIAN JOURNAL OF DIABETES (2015)
Molecular Mechanisms of Autophagy in the Cardiovascular System
Damian Gatica et al.
CIRCULATION RESEARCH (2015)
Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus
M. J. Davies et al.
DIABETES OBESITY & METABOLISM (2015)
Effects of luseogliflozin, a sodium-glucose co-transporter 2 inhibitor, on 24-h glucose variability assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, crossover study
R. Nishimura et al.
DIABETES OBESITY & METABOLISM (2015)
Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data
S. Del Prato et al.
DIABETES OBESITY & METABOLISM (2015)
Deranged sodium to sudden death
Colleen E. Clancy et al.
JOURNAL OF PHYSIOLOGY-LONDON (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pharmacodynamics, Efficacy and Safety of Sodium-Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
Andre J. Scheen
DRUGS (2015)
SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria
Yukihiro Chino et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2014)
Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors
Raymond V. Oliva et al.
JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION (2014)
Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
Donald E. Kohan et al.
KIDNEY INTERNATIONAL (2014)
Advances in understanding the interrelations between leptin resistance and obesity
Haitao Pan et al.
PHYSIOLOGY & BEHAVIOR (2014)
The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfunction in the Streptozotocin Diabetes Rat Model by Interfering with Oxidative Stress and Glucotoxicity
Matthias Oelze et al.
PLOS ONE (2014)
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial
Martin Ridderstrale et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside Review
Janet B. McGill
DIABETES THERAPY (2014)
Sodium-Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes A Systematic Review and Meta-analysis
Despoina Vasilakou et al.
ANNALS OF INTERNAL MEDICINE (2013)
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
H. J. Lambers Heerspink et al.
DIABETES OBESITY & METABOLISM (2013)
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
William T. Cefalu et al.
LANCET (2013)
Efficacy and Safety of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus
Muhammad A. Abdul-Ghani et al.
CURRENT DIABETES REPORTS (2012)
Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial
R. R. Henry et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2012)
Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
Jan Bolinder et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Elevated Cytosolic Na+ Increases Mitochondrial Formation of Reactive Oxygen Species in Failing Cardiac Myocytes
Michael Kohlhaas et al.
CIRCULATION (2010)
Oral Tolvaptan Is Safe and Effective in Chronic Hyponatremia
Tomas Berl et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Myocardial Fatty Acid Metabolism in Health and Disease
Gary D. Lopaschuk et al.
PHYSIOLOGICAL REVIEWS (2010)
Facilitative glucose transporter 9, a unique hexose and urate transporter
Manuel Doblado et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2009)
RAGE signaling in inflammation and arterial aging
Li Lin et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2009)
The Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH)
Guy Decaux
SEMINARS IN NEPHROLOGY (2009)
Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?
RJ Johnson et al.
HYPERTENSION (2003)
Share Paper
